CYTEK(US:CTKB) Newsfilter·2024-05-28 21:30Core Insights - Cytek Biosciences, Inc. has received NMPA approval for its 1-laser and 2-laser 6-color TBNK reagent cocktails for clinical diagnostic use in China, marking a significant milestone for the company [1][3] Group 1: Product and Technology - The TBNK reagents are designed for clinical use to assess and monitor immune system status, aiding in the diagnosis of various immune-related conditions such as immunodeficiencies, autoimmune diseases, infectious diseases, and cancers [2] - The TBNK assay is the first clinical 1-laser based 6-color assay supported by Full Spectrum Profiling™ (FSP™) technology, which enhances the capability of cell analysis systems [1][3] - The Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems utilize an on-board volumetric meter for absolute cell counts, reducing testing costs compared to traditional methods [3] Group 2: Market Impact and Strategy - The NMPA clearance enhances Cytek's market presence in China and opens new opportunities, strengthening its competitive advantage in the cell analysis market [3] - Cytek aims to continue seeking regulatory approvals in additional geographies to broaden the availability of its cell analysis solutions for clinical use [3][4] Group 3: Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing patented Full Spectrum Profiling™ technology to deliver high-resolution and high-sensitivity cell analysis tools [4] - The company's product portfolio includes core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as various reagents and software solutions [4]